TriSalus Life Sciences IPO

TriSalus Life Sciences is a biopharma company that specializes in treatment research and development for tumors of the liver and pancreas. TriSalus involves a team of clinicians and scientists who develop systemic immunotherapies to fight tumors through its developed drug delivery methods.

Register for Details

For more details on financing and valuation for TriSalus Life Sciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about TriSalus Life Sciences

Forge green plus iconForge green minus icon

What is TriSalus Life Sciences's IPO price?

TriSalus Life Sciences's IPO price is $8.3 as of 1/18/24.
Forge green plus iconForge green minus icon

What is TriSalus Life Sciences's funding to date?

TriSalus Life Sciences has raised $198.81MM to date.
Forge green plus iconForge green minus icon

When was TriSalus Life Sciences founded?

TriSalus Life Sciences was founded in 2009.

TriSalus Life Sciences Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
10/5/2022 Series B-2 $15.32MM raised $XXX.XX $XXX.XX
9/29/2021 Series B-1 and B-3 $40.64MM raised $XXX.XX $XXX.XX
3/18/2021 Series B $85.22MM raised $XXX.XX $XXX.XX
3/2/2017 Series A-6 $16.3MM raised $XXX.XX $XXX.XX
12/2/2015 Series A-4 and A-5 $15.12MM raised $XXX.XX $XXX.XX
11/7/2013 Series A-2 and A-3 $19.68MM raised $XXX.XX $XXX.XX
7/6/2011 Series A-1 $6.53MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.